Last reviewed · How we verify

CM-CS1 T-cell infusion

Celyad Oncology SA · Phase 1 active Biologic

CM-CS1 T-cell infusion is a Biologic drug developed by Celyad Oncology SA. It is currently in Phase 1 development.

At a glance

Generic nameCM-CS1 T-cell infusion
SponsorCelyad Oncology SA
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about CM-CS1 T-cell infusion

What is CM-CS1 T-cell infusion?

CM-CS1 T-cell infusion is a Biologic drug developed by Celyad Oncology SA.

Who makes CM-CS1 T-cell infusion?

CM-CS1 T-cell infusion is developed by Celyad Oncology SA (see full Celyad Oncology SA pipeline at /company/celyad-oncology-sa).

What development phase is CM-CS1 T-cell infusion in?

CM-CS1 T-cell infusion is in Phase 1.

Related